Larsson R - Search Results

1

Antitumor activity of the alkylating oligopeptides J1 (L-melphalanyl-p-L-fluorophenylalanine ethyl ester) and P2 (L-prolyl-m-L-sarcolysyl-p-L-fluorophenylalanine ethyl ester): comparison with melphalan.

Gullbo J, Dhar S, Luthman K, Ehrsson H, Lewensohn R, Nygren P, Larsson R. Gullbo J, et al. Among authors: larsson r. Anticancer Drugs. 2003 Sep;14(8):617-24. doi: 10.1097/00001813-200309000-00006. Anticancer Drugs. 2003. PMID: 14501383

2

Activity of hydrolytic enzymes in tumour cells is a determinant for anti-tumour efficacy of the melphalan containing prodrug J1.

Gullbo J, Wickström M, Tullberg M, Ehrsson H, Lewensohn R, Nygren P, Luthman K, Larsson R. Gullbo J, et al. Among authors: larsson r. J Drug Target. 2003 Jul;11(6):355-63. doi: 10.1080/10611860310001647140. J Drug Target. 2003. PMID: 14668056

3

Antitumor activity of the novel melphalan containing tripeptide J3 (L-prolyl-L-melphalanyl-p-L-fluorophenylalanine ethyl ester): comparison with its m-L-sarcolysin analogue P2.

Gullbo J, Wallinder C, Tullberg M, Lövborg H, Ehrsson H, Lewensohn R, Nygren P, Luthman K, Larsson R. Gullbo J, et al. Among authors: larsson r. Mol Cancer Ther. 2003 Dec;2(12):1331-9. Mol Cancer Ther. 2003. PMID: 14707274

4

Structure-activity relationship for alkylating dipeptide nitrogen mustard derivatives.

Gullbo J, Tullberg M, Våbenø J, Ehrsson H, Lewensohn R, Nygren P, Larsson R, Luthman K. Gullbo J, et al. Among authors: larsson r. Oncol Res. 2003;14(3):113-32. doi: 10.3727/000000003771013071. Oncol Res. 2003. PMID: 14760861

5

Development and characterization of two human tumor sublines expressing high-grade resistance to the cyanoguanidine CHS 828.

Gullbo J, Lövborg H, Dhar S, Lukinius A, Oberg F, Nilsson K, Björkling F, Binderup L, Nygren P, Larsson R. Gullbo J, et al. Among authors: larsson r. Anticancer Drugs. 2004 Jan;15(1):45-54. doi: 10.1097/00001813-200401000-00008. Anticancer Drugs. 2004. PMID: 15090743

6

Cytotoxic effect in vivo and in vitro of CHS 828 on human myeloma cell lines.

Hovstadius P, Lindhagen E, Hassan S, Nilsson K, Jernberg-Wiklund H, Nygren P, Binderup L, Larsson R. Hovstadius P, et al. Among authors: larsson r. Anticancer Drugs. 2004 Jan;15(1):63-70. doi: 10.1097/00001813-200401000-00010. Anticancer Drugs. 2004. PMID: 15090745

7

Antitumor efficacy and acute toxicity of the novel dipeptide melphalanyl-p-L-fluorophenylalanine ethyl ester (J1) in vivo.

Gullbo J, Lindhagen E, Bashir-Hassan S, Tullberg M, Ehrsson H, Lewensohn R, Nygren P, De La Torre M, Luthman K, Larsson R. Gullbo J, et al. Among authors: larsson r. Invest New Drugs. 2004 Nov;22(4):411-20. doi: 10.1023/B:DRUG.0000036683.10945.bb. Invest New Drugs. 2004. PMID: 15292711

8

In vitro drug resistance in B cell chronic lymphocytic leukemia: a comparison with acute myelocytic and acute lymphocytic leukemia.

Aleskog A, Larsson R, Höglund M, Kristensen J, Nygren P, Lindhagen E. Aleskog A, et al. Among authors: larsson r. Anticancer Drugs. 2005 Mar;16(3):277-83. doi: 10.1097/00001813-200503000-00006. Anticancer Drugs. 2005. PMID: 15711179

9

Screening for apoptosis--classical and emerging techniques.

Lövborg H, Gullbo J, Larsson R. Lövborg H, et al. Among authors: larsson r. Anticancer Drugs. 2005 Jul;16(6):593-9. doi: 10.1097/00001813-200507000-00001. Anticancer Drugs. 2005. PMID: 15930885 Review.

10

Predictive value of in vitro assessment of cytotoxic drug activity in advanced breast cancer.

Villman K, Blomqvist C, Larsson R, Nygren P. Villman K, et al. Among authors: larsson r. Anticancer Drugs. 2005 Jul;16(6):609-15. doi: 10.1097/00001813-200507000-00003. Anticancer Drugs. 2005. PMID: 15930887

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

526 results

Search Page

Filters